The pharmaceutical industry is under increasing pressure to deliver new medicines quickly and cost effectively; traditional small molecule product pipelines have dried up and companies are increasingly investing into biopharmaceuticals. To date, the most successful biopharmaceuticals have been monoclonal antibodies. The ability to construct common manufacturing platforms for a range of antibody products has underpinned this interest. Antibodies are most often produced as heterologous proteins at large scale in stirred tank reactors. However, at manufacturing scale there is limited opportunity to undertake process development and optimisation. If a manufacturing process can be ‘scaled down’ experiments could be carried out at much greater th...
The use of N-1 perfusion, coupled with high-inoculum fed batch in CHO cell culture manufacturing pro...
For cultivation of mammalian cells in biopharmaceutical research and manufacturing, single-use techn...
Recent improvements in volumetric antibody productivity (often in excess of 5 g/L) have been achieve...
To accelerate cell culture process development, most companies have validated scale-down models of t...
The continuous production of biopharmaceuticals combines several advantages: the use of smaller equi...
Monoclonal antibodies (mAbs) have become vitally important to modern medicine and are currently one ...
The maturation of biopharmaceutical process understanding and technical advances have paved the way ...
The increased use of antibodies for human therapy has driven rational approaches to accelerate biop...
AbstractThe need to bring new biopharmaceutical products to market more quickly and to reduce final ...
Monoclonal antibodies (mAbs) are key molecules in biopharmaceutical manufacturing with important the...
The rapid increase in the number of monoclonal antibodies (mAbs) which are being regularly approved...
The demand for commercially valuable biopharmaceuticals able to treat different immunopathological d...
Micro scale, high throughput perfusion technology is under-developed and not widely utilised in acad...
The advancement of microbioreactor technology in recent years has transformed early- and mid-stage p...
Tobacco BY-2 cells have emerged as a promising platform for the manufacture of biopharmaceutical pro...
The use of N-1 perfusion, coupled with high-inoculum fed batch in CHO cell culture manufacturing pro...
For cultivation of mammalian cells in biopharmaceutical research and manufacturing, single-use techn...
Recent improvements in volumetric antibody productivity (often in excess of 5 g/L) have been achieve...
To accelerate cell culture process development, most companies have validated scale-down models of t...
The continuous production of biopharmaceuticals combines several advantages: the use of smaller equi...
Monoclonal antibodies (mAbs) have become vitally important to modern medicine and are currently one ...
The maturation of biopharmaceutical process understanding and technical advances have paved the way ...
The increased use of antibodies for human therapy has driven rational approaches to accelerate biop...
AbstractThe need to bring new biopharmaceutical products to market more quickly and to reduce final ...
Monoclonal antibodies (mAbs) are key molecules in biopharmaceutical manufacturing with important the...
The rapid increase in the number of monoclonal antibodies (mAbs) which are being regularly approved...
The demand for commercially valuable biopharmaceuticals able to treat different immunopathological d...
Micro scale, high throughput perfusion technology is under-developed and not widely utilised in acad...
The advancement of microbioreactor technology in recent years has transformed early- and mid-stage p...
Tobacco BY-2 cells have emerged as a promising platform for the manufacture of biopharmaceutical pro...
The use of N-1 perfusion, coupled with high-inoculum fed batch in CHO cell culture manufacturing pro...
For cultivation of mammalian cells in biopharmaceutical research and manufacturing, single-use techn...
Recent improvements in volumetric antibody productivity (often in excess of 5 g/L) have been achieve...